

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived mouse IL-6/IL-6R alpha Complex protein		
	Mouse IL-6R alpha (Leu20-Glu357) Accession # P22272	GGGSGGGSGGGS	Mouse IL-6 (Phe25-Thr211) Accession # P08505
	N-terminus		C-terminus
N-terminal Sequence Analysis	Leu20 (major), Leu28 (minor)		
Predicted Molecular Mass	60 kDa		


SPECIFICATIONS

SDS-PAGE	70-87 kDa, reducing conditions
Activity	Measured by its ability to inhibit M1 mouse myeloid leukemia cell proliferation. The ED ₅₀ for this effect is 2-12 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 200 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Interleukin-6 (IL-6) is a pleiotropic, α -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6, along with TNF- α and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1-3). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 6). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R α , triggering IL-6 R α association with gp130 and gp130 dimerization (7). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (8). Soluble forms of IL-6 R α are generated by both alternative splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R α elicit responses from gp130-expressing cells that lack cell surface IL-6 R α (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R α is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R α but not from other cytokines that use gp130 as a co-receptor (3, 9). Mature mouse IL-6 shares 39% and 85% amino acid (aa) sequence identity with human and rat IL-6, respectively (10-12). Within the extracellular domain, mouse IL-6 R α shares 51% and 89% aa sequence identity with human and rat IL-6 R α , respectively (13).

References:

1. Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. **24**:249.
2. Schuett, H. *et al.* (2009) Thromb. Haemost. **102**:215.
3. Hunter, C.A. and S.A. Jones (2015) Nat. Immunol. **16**:448.
4. Erta, M. *et al.* (2012) Int. J. Biol. Sci. **8**:1254.
5. Garbers, C. *et al.* (2012) Cytokine Growth Factor Rev. **23**:85.
6. Cerutti, A. *et al.* (1998) J. Immunol. **160**:2145.
7. Murakami, M. *et al.* (1993) Science **260**:1808.
8. Muller-Newen, G. (2003) Sci. STKE **2003**:PE40.
9. Mitsuyama, K. *et al.* (2006) Clin. Exp. Immunol. **143**:125.
10. Chiu, C.P. *et al.* (1988) Proc. Natl. Acad. Sci. USA **85**:7099.
11. Simpson, R.J. *et al.* (1988) Eur. J. Biochem. **176**:187.
12. Van Snick, J. *et al.* (1988) Eur. J. Immunol. **18**:193.
13. Sugita, T. *et al.* (1990) J. Exp. Med. **171**:2001.